2026.01- 至今 中科院广州生物医药与健康研究院，研究员，
中国-新西兰生物医药与健康“一带一路”联合实验室，课题组长
2020.01-2025.12 中科院广州生物医药与健康研究院，研究员
呼吸疾病全国重点实验室，课题组长
2018.01-2019.12 中科院广州生物医药与健康研究院，研究员
2013.01-2017.12 中科院广州生物医药与健康研究院，副研究员
2010.07-2012.12 中科院广州生物医药与健康研究院，助理研究员
2005.09-2010.06 中科院广州生物医药与健康研究院，生物技术与医药，博士
2001.09-2005.06 南京大学，环境科学，学士
运用黏膜疫苗技术研究蚊媒黄病毒、恶性肿瘤及过敏性疾病的预防或治疗手段。针对登革等新突发蚊媒黄病毒，研制无ADE风险且适于口服递送的新一代疫苗；针对胰腺癌等难治性肿瘤，研制治疗性mRNA疫苗及免疫增效策略；针对花粉及尘螨过敏，研制基于改良过敏原的治疗性疫苗；同时，设计靶向训练免疫的广谱抗病毒新策略。
[1] 中国科学院战略性先导科技专项，XDB13250301，治疗性mRNA疫苗开发，925.74万元，2025.2-2028.1，子课题主持（在研）。
[2] 国家自然科学基金（面上项目，32571715），基因组节段化消除水泡性口炎病毒（VSV）神经毒性并提升溶瘤活性的机制探索，50万元，2026.1-2029.12，主持（在研）。
[3] 国家自然科学基金（面上项目，32370998），运用环状RNA携载EDIII及NS1抗原探索安全强效的寨卡病毒疫苗，50万元，2024.1-2027.12，主持（在研）。
[4] 国家自然科学基金（国际合作项目，82061138006），新型冠状病毒诱导黏膜免疫的机制及预防治疗策略研究，300万元，2021.1-2023.12, 主持（结题）。
[5] 广东省自然科学基金（面上项目，2023A1515011468），基于环状RNA的寨卡病毒疫苗研究，10万元，2023.01.01-2025.12.31，主持（在研）。
[6] 国家自然科学基金（面上项目，31470892），新型流感病毒载体艾滋病疫苗诱导黏膜免疫反应的作用及机制研究，85万元，2015.1-2018.12，主持（结题）。
[7] 国家自然科学基金（青年基金，31200693），以分泌型PD1阻断PD/PD-L信号通路提高SIV辅助调控蛋白免疫原性的研究，25万元，2013.1-2015.12，主持（结题）。
[8] 国家重点研发计划（2016YFC1200900），重要新发突发病原体应急处置技术与产品研究，112万元，2016.7-2018.12， 分任务主持（结题）。
[9] 国家重大传染病专项（2017ZX10204401），抗H7N9病毒血浆在H7N9感染重症治疗的临床应用，195万元，2017.1-2020.12，分任务主持（结题）。
[10] “珠江科技新星”专项（201506010076），多抗原联用的多价治疗性结核疫苗研究，2015.4-2018.3，主持（结题）。
[11] 广州市健康医疗协同创新重大专项（201400000002），呼吸道新发突发及重大传染病综合防诊治，80万元，2014.3-2017.2，子课题主持（结题）。
[12] 广州市健康医疗协同创新重大专项（201508020252，201803040004），病毒感染重症救治的特异性被动免疫应用研究及腺病毒单克隆抗体药物研发，225万元+145万元（2014.11-2017.10；2018.04-2021.03），子课题主持（结题）。
[13] 广东省防控寨卡病毒病科技公关专项，寨卡病毒病原学与免疫学研究，100万元，2016.3-2018.2，主持（结题）。
[1] Ying Feng, Tao Shu, Liang Li, Xinxin Sun, Changfa Yu, Wenming Liu, Lingling Hong, Jiashun Li, Shutao Zhao, Weikai Zeng, Chenchen Yang, Chunhua Wang, Xuehua Zheng, Xianmiao Ye, Xikui Sun, Yichu Liu, Zhixia Li, Si Chen, Xuefeng Niu, Rong Zhou, Pingchao Li*, Liqiang Feng*, Ling Chen*. A replication-incompetent adenovirus type 55 vaccine induces broad and durable protective immunity against pathogenic adenoviruses. Molecular Therapy. 2026, 34(3): 1597-1615.
[2] Xikui Sun#, Huadong Jiang#, Wenqiang Yu#, Nana Wang, Zhengfeng Li, Junnan Lu, Xiaolu Xie, Liqiang Feng*. Multivalent display of Envelope protein domain III with Mi3 nanoparticles induces protective immunity against lethal Zika virus infection in mice. Virologica Sinica. 2026, 41(1): 182-195.
[3] Xianmiao Ye#, Junnan Lu#*, Zirong Han, Zhishan Fan, Xinru Hu, Lichuang Jiao, Lisha Deng, Wenming Liu, Junqi Liu, Weiqi Pan, Ling Chen, Liqiang Feng*, Caijun Sun*. A semi-replicating VSV (srVSV)-based platform for developing broad-spectrum mucosal vaccines against influenza A viruses. Virologica Sinica. 2026, 41(2): 423-438.
[4] Weiqi Deng, Xuefeng Niu, Ping He, Qihong Yan, Huan Liang, Yongping Wang, Lishan Ning, Zihan Lin, Yudi Zhang, Xinwei Zhao, Liqiang Feng*, Linbing Qu*, Ling Chen*. An allelic atlas of immunoglobulin heavy chain variable regions reveals antibody binding epitope preference resilient to SARS-CoV-2 mutation escape. Frontiers in Immunology. 2025, 15:1471396.
[5] Xinglong Liu# , Zhengfeng Li#, Xiaoxia Li#, Weixuan Wu, Huadong Jiang, Yufen Zheng, Junjie Zhou, Xianmiao Ye, Junnan Lu, Wei Wang, Lei Yu, Yiping Li, Linbing Qu, Jianhua Wang, Feng Li, Ling Chen*, Linping Wu*, Liqiang Feng*. A single-dose circular RNA vaccine prevents Zika virus infection without enhancing dengue severity in mice. Nature Communications. 2024, 15(1): 8932.
[6] Xinglong Liu#, Zhengfeng Li#, Xiao Li#, Xiaoyan Zhang, Yali Zheng, Wan Su, Ying Feng, Yutong Liu, Weixuan Wu, Xikui Sun, Nana Wang, Xianmiao Ye, Zhichao Zhou, Wenkuan Liu, Jun He, Wei Wang, Linbing Qu, Rong Zhou*, Ling Chen*, Liqiang Feng*. Neutralizing monoclonal antibodies protect against human adenovirus type 55 infection in transgenic mice and tree shrews. Emerging Microbes & Infections. 2024, 13(1):2307513.
[7] Pingchao Li#*, Qian Wang#, Yizi He#, Chenchen Yang#, Zhengyuan Zhang, Zijian Liu, Bo Liu, Li Yin, Yilan Cui, Peiyu Hu, Yichu Liu, Pingqian Zheng, Wei Wang, Linbing Qu, Caijun Sun, Suhua Guan, Liqiang Feng*, Ling Chen*. Booster vaccination is required to elicit and maintain COVID-19 vaccine-induced immunity in SIV-infected macaques. Emerging Microbes & Infections. 2023, 12(1): e2136538.
[8] Xianmiao Ye#, Xinglong Liu#, Tao Shu, Weiqi Deng, Min Liao, Yali Zheng, Xuehua Zheng, Xiaoyan Zhang, Ting Li, Wenxia Fan, Linbing Qu, Ling Chen, Feng Li*, Liqiang Feng*. A Live-Attenuated Zika Virus Vaccine with High Production Capacity Confers Effective Protection in Neonatal Mice. Journal of Virology. 2021, 95(14):e0038321.
[9] Jinlin Wang#, Tao Shu#, Weiqi Deng, Yali Zheng, Min Liao, Xianmiao Ye, Lujie Han, Ping He, Xuehua Zheng, Ting Li, Ying Feng, Fengyu Hu, Pingchao Li, Caijun Sun, Ling Chen, Feng Li*, Liqiang Feng*. Mucosal priming with a recombinant influenza A virus-vectored vaccine elicits T-cell and antibody responses to HIV-1 in mice. Journal of Virology. 2021, 95(12):e00059-21.
[10] Tianxing Ji#*, Ling Li#, Wenrui Li, Xuehua Zheng, Xianmiao Ye, Hongliang Chen, Qiang Zhou, Hongyun Jia, Bo Chen, Zhen Lin, Haoyu Chen, Shiwen Huang, Donald Seto, Ling Chen*, Liqiang Feng*. Emergence and characterization of a putative novel human adenovirus recombinant HAdV-C104 causing pneumonia in Southern China. Virus Evolution. 2021, 7(1):veab018.
[11] Lei Yu#, Xinglong Liu#, Xianmiao Ye#, Wan Su, Xiaoyan Zhang, Weiqi Deng, Jia Luo, Mengrong Xiang, Wenjing Guo, Shengnan Zhang, Wei Xu, Qihong Yan, Qian Wang, Yilan Cui, Caixia Wu, Wenjing Guo, Xuefeng Niu, Fuchun Zhang, Chunliang Lei, Linbing Qu, Ling Chen*, Liqiang Feng*. Monoclonal Antibodies against Zika Virus NS1 Protein Confer Protection via Fcγ Receptor-dependent and -independent Pathways. mBio. 2021, 12(1):e03179-20.
[12] Liqiang Feng#, Qian Wang#, Chao Shan#, Chenchen Yang, Ying Feng, Jia Wu, Xiaolin Liu, Yiwu Zhou, Rendi Jiang, Peiyu Hu, Xinglong Liu, Fan Zhang, Pingchao Li, Xuefeng Niu, Yichu Liu, Xuehua Zheng, Jia Luo, Jing Sun, Yingying Gu, Bo Liu, Yongcun Xu, Chufang Li, Weiqi Pan, Jincun Zhao, Changwen Ke, Xinwen Chen, Tao Xu, Nanshan Zhong, Suhua Guan*, Zhiming Yuan*, Ling Chen*. An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques. Nature Communicatons. 2020, 11(1): 4207
[13] Ying Feng#, Changhua Yi#, Xinglong Liu#, Linbing Qu, Wan Su, Tao Shu, Xuehua Zheng, Xianmiao Ye, Jia Luo, Mingli Hao, Xikui Sun, Liang Li, Xiaolin Liu, Chenchen Yang, Suhua Guan, Ling Chen and Liqiang Feng*. Human desmoglein-2 and human CD46 mediate HAdV55 infection but human desmoglein-2 plays the major roles. Journal of Virology. 2020, 94(17): e00747-20.
[14] Tianxing Ji#*, Ying Liu#, Yaqing Li, Shahzad Akbar Khan, Qiang Zhou, Bo Chen, Zhen Lin, Xingchen Wang, Xianmiao Ye, Xuehua Zheng, Ling Chen*, Liqiang Feng*. Molecular typing and genomic characteristic of human adenoviruses in Datong, Northern China. Journal of Medical Virology. 2020, 92(12): 3111-3118.
[15] Xianmiao Ye, Lijun Xiao, Xuehua Zheng, Jinlin Wang, Tao Shu, Ying Feng, Xinglong Liu, Wan Su, Qian Wang, Chufang Li, Ling Chen* and Liqiang Feng*. Seroprevalence of Neutralizing Antibodies to Human Adenovirus Type 4 and 7 in Healthy Populations from Southern China. Frontiers in Microbiology. 2018, 9:3040.
[16] Xinglong Liu#, Linbing Qu#, Xianmiao Ye#, Changhua Yi, Xuehua Zheng, Mingli Hao, Wan Su, Zhipeng Yao, Peihai Chen, Shengnan Zhang, Yupeng Feng, Qian Wang, Qihong Yan, Pingchao Li, Heying Li, Feng Li, Weiqi Pan, Xuefeng Niu, Ruian Xu, Liqiang Feng* and Ling Chen*. Incorporation of NS1 and prM/M are important to confer effective protection of adenovirus-vectored Zika virus vaccine carrying E protein. NPJ Vaccines. 2018, 3:29.
[17] Yupeng Feng, Chufang Li, Peiyu Hu, Qian Wang, Xuehua Zheng, Yongkun Zhao, Yi Shi, Songtao Yang, Changhua Yi, Ying Feng, Chunxiu Wu, Linbing Qu, Wei Xu, Yao Li, Caijun Sun, Fu Geroge Gao, Xianzhu Xia, Liqiang Feng*, Ling Chen*. An adenovirus serotype 2-vectored ebolavirus vaccine generates robust antibody and cell-mediated immune responses in mice and rhesus macaques. Emerging Microbes & Infections. 2018. 7: 101.
[18] Ying Feng, Xikui Sun, Xianmiao Ye, Yupeng Feng, Jinlin Wang, Xuehua Zheng, Xinglong Liu, Changhua Yi, Mingli Hao, Qian Wang, Feng Li, Wei Xu, Liang Li, Chufang Li, Rong Zhou, Ling Chen* and Liqiang Feng*. Hexon and fiber of adenovirus type 14 and 55 are major targets of neutralizing antibody but only fiber-specific antibody contributes to cross-neutralizing activity. Virology. 2018, 518: 272–283.
[19] Yiling Zhang, Ying Feng, Liang Li, Xianmiao Ye, Jinlin Wang, Qian Wang, Pingchao Li, Na Li, Xuehua Zheng, Xiang Gao, Chufang Li, Feng Li, Baoqing Sun, Kefang Lai, Zhong Su, Nanshan Zhong, Ling Chen*, Liqiang Feng*. Immunization with an adenovirus-vectored TB vaccine containing Ag85A-Mtb32 effectively alleviates allergic asthma. Journal of Molecular Medicine. 2018, 96(3-4):249-263.
[20] Xuehua Zheng, Xia Rong, Ying Feng, Xikui Sun, Liang Li, Qian Wang, Min Wang, Wenkuan Liu, Chufang Li, Yiyu Yang, Rong Zhou, Jiahai Lu, Liqiang Feng* and Ling Chen*. Seroprevalence of neutralizing antibodies against adenovirus type 14 and 55 in healthy adults in Southern China. Emerging Microbes & Infections. 2017, 6: e43.
[21] Yiling Zhang#, Liqiang Feng#*, Liang Li, Dimin Wang, Chufang Li, Caijun Sun, Pingchao Li, Xuehua Zheng, Yichu Liu, Wei Yang, Xuefeng Niu, Nanshan Zhong & Ling Chen. Effects of the fusion design and immunization route on the immunogenicity of Ag85A-Mtb32 in adenoviral vectored tuberculosis vaccine. Human Vaccines & Immunotherapeutics. 2015, 11(7):1803-1813.
[22] Lijun Xiao, Dimin Wang, Caijun Sun, Pingchao Li, Yi Jin, Liqiang Feng*, Ling Chen*. Enhancement of SIV-specific cell mediated immune responses by co-administration of soluble PD-1 and Tim-3 as molecular adjuvants in mice. Human Vaccines & Immunotherapeutics. 2014, 10(3): 724-733.
[23] Feng Li#, Liqiang Feng#, Weiqi Pan, Zhenyuan Dong, Chufang Li, Caijun Sun, Ling Chen*. Generation of replication-competent recombinant influenza A viruses carrying a reporter gene harbored in neuraminidase segment. Journal of Virology. 2010, 84(22):12075-12081.
[24] Liqiang Feng, Feng Li, Yichu Liu, Xuehua Zheng, Biliang Zhang, Ling Chen*. A convenient plasmid-based system containing three reporter genes for real-time and quantitative analysis of messenger RNA silencing. Analytical Biochemistry. 2009, 394(2):284-286.
[25] Liqiang Feng, Feng Li, Xuehua Zheng, Weiqi Pan, Kai Zhou, Yichu Liu, Hongxuan He, Ling Chen*. The mouse Pol I terminator is more efficient than the hepatitis delta virus ribozyme in generating influenza-virus-like RNAs with precise 3’ ends in a plasmid-only-based virus rescue system. Archives of Virology. 2009, 154(7):1151-1156.
发明专利：
[1] 优化的串连细胞因子及其在诱导多能性干细胞中的应用；裴端卿，陈凌，李锋，米盖尔·埃斯特班，冯立强，谢海军，陈捷凯，秦大江；专利号：200910194191.9。（授权）
[2] 一种复制缺陷型人55型腺病毒载体及其制备方法和应用；陈凌，冯立强；专利号： 中国201510179459，美国US20180179554A1，欧洲EP3284826B1。（授权）
[3] 复制型重组人55型腺病毒载体及其制备方法和应用； 陈凌，冯立强，孙彩军，秦成峰；专利号：201410293359.2。（授权）
[4] 一种复制缺陷型14型腺病毒载体及其制备方法和应用；陈凌，冯立强，李楚芳，孙西魁；申请号：201710116966.5。（实审）
[5] 一种Ad5-M2m作为通用流感疫苗毒种的构建与制备方法；罗琴芳，陈瑞爱，黄文科，唐满华，汤钦，冯立强，潘蔚绮，陈凌；申请号：201610899659.4。（公开）
[6] 一种H7亚型重组禽流感病毒活载体疫苗毒种的制备方法；罗琴芳，冯立强，潘蔚绮，陈凌，陈瑞爱，钟南山；申请号：201610640234.1。（公开）
[7] 一种寨卡病毒疫苗及其制备方法；陈凌，冯立强；申请号：201711499584.1。（实审）
[8] 一种复制缺陷型重组人7型腺病毒及其制备方法和应用; 陈凌，冯立强；申请号：201910761908.7。（实审）
[9] 一种复制缺陷型重组人4型腺病毒及其制备方法和应用；陈凌，冯立强；申请号：201910761977.8。（实审）
[10] 一种重组寨卡病毒减毒株及其制备方法和应用；冯立强，陈凌，叶贤苗；专利号：202110214252.4。（授权）
[11] 一种节段化的水泡性口炎病毒载体及其制备方法和应用；冯立强，卢俊南；申请号：202211130204.8。（实审）
[12] 抗丝状病毒单克隆中和抗体及其制备方法和应用；陈凌，冯玉鹏，冯立强，王龙雨；专利号：ZL201910989375.8；申请日期：2019.10.17。（授权）
[13] 一种抗丝状病毒GP蛋白的单克隆抗体及其应用；陈凌，王龙雨，冯立强，冯玉鹏；专利号：ZL201910962914.9；申请日期：2019.10.11。（授权）
[14] 一种特异性结合HAdV55的抗体或抗原结合片段及其应用；冯立强，刘兴龙，张小燕，苏婉，陈凌；申请号：202311813093.5；申请日期：2023.12.27。（申请）
[15] 一种登革和/或寨卡病毒基因工程疫苗及其制备方法和应用；冯立强，蒋华东；申请号：2026103023421；申请日期：2026.3.12。（申请）
